ASCO Concerned With MIPS Part B Reimbursement Assessments in QPP Proposal

Get Permission

ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on its proposed rule outlining changes to the Quality Payment Program (QPP) for 2018. In a letter to CMS Administrator Seema Verma, ASCO President Bruce E. Johnson, MD, FASCO, made recommendations regarding the two major paths for physician reimbursement within QPP: the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APMs).

The proposed rule includes a provision that could make certain Medicare Part B drug reimbursements subject to MIPS adjustments and seriously increase financial penalties for oncology practices. ASCO urges CMS to refrain from implementing such a policy at any point in time and to measure adherence to high-quality clinical pathways as a quality metric, rather than using raw, unadjusted oncology cost data for anticancer drugs. ASCO also supports efforts to develop oncology-specific episodes for evaluating resource use under MIPS.

ASCO strongly urges the Center for Medicare and Medicaid Innovation to implement multiple oncology-focused APMs, including ASCO’s Patient-Centered Oncology Payment (PCOP) model. Testing multiple oncology-specific APMs is necessary to meet the needs of a diverse Medicare population and to allow oncologists to evaluate models and choose the best approach for their patients and practices. ■

©2017. American Society of Clinical Oncology. All rights reserved.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.